Milk Thistle

Silybum marianum (L.) Gaertn. is a member of Asteraceae, the daisy family, which matters for allergy. NCCIH lists Carduus marianus as a synonym and Mary thistle and holy thistle as common names; MSKCC adds lady’s thistle and Marian thistle. NCBI Taxonomy files it as taxon 92921. It is an annual or biennial that forms a rosette of large, glossy, spiny-edged leaves boldly marbled with white along the veins, then sends up a flowering stem that can reach well over a metre. Each stem ends in a large reddish-purple flower head wrapped in stiff, spine-tipped bracts. NCCIH describes it as native to Europe and introduced to North America by early colonists. It now grows as a weed of disturbed ground in many warm temperate regions.

The medicinal part is the ripe fruit, a hard, shiny, mottled achene a few millimetres long, with its silky pappus removed. The European Pharmacopoeia standard sets a minimum silymarin content, expressed as silibinin, for the dried fruit, and the EU monograph lists teas, powdered fruit, and a range of dry extracts made with acetone, ethanol, ethyl acetate, or methanol at drug-to-extract ratios between 20:1 and 70:1. Those ratios explain why a milk thistle capsule can contain very different amounts of active material: dried fruit and concentrated extract are not interchangeable.

Silymarin is not one compound. Wah Kheong and colleagues describe it as a complex mixture of six major flavonolignans plus minor polyphenols: silybin A and silybin B (together called silibinin or silybin; PubChem CID 31553, C25H22O10), isosilybin A and B, silychristin, and silydianin, along with the flavonoid taxifolin (CID 439533). Silibinin is usually the largest component and the one most studied. Silymarin dissolves poorly in water and is poorly absorbed by mouth, which has led to formulations that bind silybin to phosphatidylcholine or otherwise try to improve absorption. Comparisons between trials using different products are therefore rough.

Quality is a real problem. NCCIH notes concerns about the chemical and microbiological quality of milk thistle supplements in the United States and elsewhere. Fenclova and colleagues (Scientific Reports 2019) tested 26 milk thistle supplements bought in the US and the Czech Republic and found large differences in silymarin content, often at odds with the label, substantial batch-to-batch variation, and mycotoxins, pesticide residues, and microbial contamination across the products tested. A supplement taken to protect the liver should not deliver mould toxins to it.

NCCIH notes that milk thistle was historically used for liver disorders and to increase breast milk production. Classical and medieval European authors describe thistles in their herbals, and the identification with Silybum is usually made from descriptions of the white-veined leaves. The common names carry a Christian legend: the white marbling was said to come from drops of the Virgin Mary’s milk, giving Mary thistle, Marian thistle, and lady’s thistle. The same legend supports the old use as a galactagogue, an herb to increase milk supply. By the early modern period, English and German herbals recommended the plant for jaundice, obstructions of the liver and spleen, and melancholy, ideas built on humoral medicine rather than tests of liver function.

The modern story is German pharmacology. In the twentieth century, German researchers isolated and characterized silymarin and its components, and standardized extracts entered pharmacies there and across Europe as liver medicines. Laboratory work showing that silymarin protects animal livers from carbon tetrachloride, alcohol, and other toxins drove clinical studies in alcoholic cirrhosis and hepatitis from the 1970s onward. Ferenci’s 1989 trial in Vienna, which reported better four-year survival in cirrhosis, became the most cited positive result; Parés’s larger 1998 trial in Spain, which found no survival effect in alcoholic cirrhosis, became the most cited negative one.

Mushroom poisoning gave silibinin its hospital role. Intravenous silibinin, marketed in Europe as Legalon SIL, has been used for decades to treat amatoxin poisoning from death cap (Amanita phalloides) and related mushrooms, on the basis of case series rather than controlled trials. In the United States the supplement boom of the 1990s made milk thistle one of the best-known liver herbs. NIH-funded trials then tested silymarin properly: the SyNCH trial in hepatitis C (published 2012) and a separate trial in NASH (published 2019) both missed their primary end points. The EU’s Committee on Herbal Medicinal Products adopted its monograph on 5 June 2018, granting traditional use only.

Laboratory and animal studies describe several actions. MSKCC’s summary cites antioxidant and anti-inflammatory effects of silibinin, including reduced release of hydrogen peroxide and tumour necrosis factor alpha; antifibrotic effects through downregulation of collagen and other extracellular matrix proteins in animal models; and activity against hepatitis C virus entry in cell studies. Silymarin and silibinin also show estrogenic activity with a preference for estrogen receptor beta. None of these has been shown to translate into better outcomes in human liver disease, and doses in animal studies are often far higher than what people absorb from capsules.

The death cap mechanism is better defined. Amatoxins are taken up into liver cells through specific transporters and recirculate between liver and gut. Mengs and colleagues (Current Pharmaceutical Biotechnology 2012) describe silibinin as interacting with hepatic transport proteins to block the re-uptake of amatoxin into liver cells, interrupting that enterohepatic circulation. That effect requires intravenous silibinin at high doses given early, as part of aggressive supportive care. It is not something an oral supplement can reproduce, and it does not imply that silymarin protects the liver from alcohol, medicines, or fat.

On drug metabolism, MSKCC notes that milk thistle inhibits CYP3A4 in some studies, while other studies show no effect, and that silybin and isosilybin inhibited PXR-mediated induction of CYP3A4 in the laboratory. In a clinical study it did not reduce levels of the HIV drug indinavir. Milk thistle also modulates UGT enzymes in vitro. Overall, the interaction signal is weak and inconsistent, quite unlike St. John’s wort.

Alcoholic and viral liver disease: Rambaldi, Jacobs, and Gluud (Cochrane 2007) reviewed 18 randomized trials with 1,088 patients. Methodological quality was low. Milk thistle had no significant effect on mortality (relative risk 0.78), complications of liver disease (0.95), or liver histology. Liver-related mortality was lower across all trials (0.50) but not in high-quality trials (0.57, not significant). Adverse events were no more common than with placebo. In cirrhosis, Ferenci and colleagues (Journal of Hepatology 1989) randomized 170 patients to 140 mg of silymarin three times daily or placebo and reported four-year survival of 58% versus 39%, with benefit concentrated in alcoholic cirrhosis and milder disease. Parés and colleagues (Journal of Hepatology 1998) randomized 200 alcoholics with cirrhosis to 150 mg three times daily or placebo and found survival similar in both groups, with no effect on the course of the disease.

Hepatitis C and NASH: the NCCIH-funded trials tested higher-than-customary doses of a standardized silymarin product (Legalon). Fried and colleagues (JAMA 2012) randomized 154 people with chronic hepatitis C who had not responded to interferon to 420 mg, 700 mg, or placebo three times daily for 24 weeks; only two participants in each group met the primary ALT target, and there were no differences in liver enzymes, viral load, or quality of life. Navarro and colleagues (PLoS One 2019) randomized 78 people with NASH without cirrhosis to 420 mg, 700 mg, or placebo three times daily for 48 weeks; 15%, 19%, and 12% reached the histological primary end point, a non-significant difference, though many participants turned out not to meet entry criteria on central review. In Malaysia, Wah Kheong and colleagues (Clinical Gastroenterology and Hepatology 2017) randomized 99 people with biopsy-proven NASH to 700 mg three times daily or placebo for 48 weeks; the primary end point was not met (32.7% versus 26.0%), but fibrosis improved by at least one stage in 22.4% versus 6.0%. That fibrosis signal needs confirmation in a larger trial.

Diabetes: NCCIH notes small studies, mostly from the Middle East, suggesting milk thistle may help blood sugar control in type 2 diabetes. Voroneanu and colleagues (Journal of Diabetes Research 2016) pooled five trials with 270 patients and found lower fasting glucose (about 27 mg/dL) and HbA1c (about 1.1 percentage points) with silymarin, but judged the evidence too low in quality and too heterogeneous to make a recommendation. Effects that large would be clinically meaningful if replicated; so far they have not been in well-powered trials elsewhere.

Other claims: NCCIH says it is unclear whether milk thistle affects breast milk production and unknown whether it helps other conditions. MSKCC lists small studies on chemotherapy-related liver toxicity, neuropathy, hand-foot syndrome, radiation dermatitis, and acne, none strong enough to guide care. The EU traditional indication is narrow: symptomatic relief of digestive disorders such as fullness and indigestion, and to support liver function, after serious conditions have been excluded by a doctor. Liver cleanses and detox products that contain milk thistle have no evidence base as products, and some have caused harm through other ingredients or interactions. Death cap poisoning is a medical emergency treated with intravenous silibinin in hospital; it is never a reason to take milk thistle capsules at home.

EU traditional use (EMA/HMPC/294187/2013, adopted 5 June 2018): tea, 3–5 g of crushed fruit in 100 ml of boiling water, two to three times daily before meals; powdered fruit, 300–600 mg two to three times daily, up to 1,800 mg per day; or one of several dry extracts at doses that depend on the extract, for example an acetone extract (DER 20–70:1) at 82–239 mg two to three times daily, up to 478 mg per day, or a 96% ethanol extract (DER 30–40:1) at 200 mg once daily. Take before meals. Not recommended under 18. If symptoms persist beyond two weeks, see a doctor or qualified practitioner. The monograph lists no well-established use.

In trials, doses have ranged from 140–150 mg of silymarin three times daily in the older cirrhosis studies to 420–700 mg three times daily in the NCCIH-funded hepatitis C and NASH trials. Those higher doses were well tolerated, which is reassuring for safety, but did not produce benefit on primary outcomes. US supplements commonly state an amount of extract standardized to a percentage of silymarin, often 70–80%, which is a manufacturer specification rather than a pharmacopoeial requirement. Independent testing has found many products far from their label claims.

Choose products that name the plant part (fruit or seed), the extract, its silymarin content, and an independent quality certification, given the contamination findings. Avoid multi-ingredient liver cleanse or detox blends, which add unknown risks; MSKCC cites a case in which a liver cleanse supplement containing milk thistle raised a patient’s INR on warfarin from 2.64 to 4.12. Silymarin is not a substitute for hepatitis B or C antiviral treatment, which now cures most hepatitis C and controls hepatitis B.